Intercept Pharmaceuticals names Lazar Partners AOR

NEW YORK: Intercept Pharmaceuticals has named Lazar Partners as its AOR.

NEW YORK: Intercept Pharmaceuticals has named Lazar Partners as its AOR.

Intercept has a wide portfolio of products that focus on both orphan and prevalent liver and intestinal diseases.

The agency is planning to communicate Intercept’s medical advances and products to key stakeholders.

 

Would you like to post a comment?

Please Sign in or register.

News by email...